46. Yupelri

Theravance logo

Active ingredient: revefenacin 
Disease: chronic obstructive pulmonary disorder
Peak sales estimate: $250 million 
Approved: Nov. 8 
Company: Mylan and Theravance 

The scoop: In November, Theravance and Mylan’s Yupelri became the first once-daily, nebulized bronchodilator for chronic obstructive pulmonary disorder (COPD). But the long-acting muscarinic antagonist (LAMA) will face an uphill battle in a crowded COPD market, according to Brian Skorney, an analyst at Baird Equity Research, who predicted its peak sales to exceed $250 million in 2030. “We think the opportunity for a nebulized LAMA is relatively limited by the treatment paradigm in COPD, where combination therapy is the mainstay and there is wide availability of numerous inhalers containing two-three mechanisms in one,” he wrote in a note. But this won’t be the first hurdle for revefenacin—GlaxoSmithKline acquired the rights to the drug back in 2004, but dumped it after finding its formulation was not compatible with the company’s proprietary inhaler. — Amirah Al Idrus

46. Yupelri

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.